Education
About Us
Working with TipRanks
Follow Us
ReShape Lifesciences (RSLS)
NASDAQ:RSLS
RSLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.23 - $324.31
Previous CloseN/A
Volume8.33K
Average Volume (3M)3.05M
Market Cap
$7.21M
Enterprise Value$4.41M
Total Cash (Recent Filing)$2.52M
Total Debt (Recent Filing)$130.00K
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.98
Shares Outstanding2,385,960
10 Day Avg. Volume334,351
30 Day Avg. Volume3,053,476
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue0.14
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ReShape Lifesciences News
PremiumCompany Announcements
ReShape Lifesciences Announces Merger with Vyome Therapeutics
PremiumCompany Announcements
ReShape Lifesciences Loans $200K to Vyome Therapeutics
PremiumCompany Announcements
ReShape Lifesciences Raises Equity to Avoid Delisting
PremiumCompany Announcements
ReShape Lifesciences Closes $2.6M Stock OfferingOptions Prices
Currently, No data available
---
Ownership Overview
9.33% Insiders
0.13% Mutual Funds
― Other Institutional Investors
90.54% Public Companies and
Individual Investors
RSLS FAQ
What was ReShape Lifesciences’s price range in the past 12 months?
ReShape Lifesciences lowest stock price was $2.23 and its highest was $324.31 in the past 12 months.
What is ReShape Lifesciences’s market cap?
ReShape Lifesciences’s market cap is $7.21M.
When is ReShape Lifesciences’s upcoming earnings report date?
ReShape Lifesciences’s upcoming earnings report date is Aug 18, 2025 which is in 25 days.
How were ReShape Lifesciences’s earnings last quarter?
ReShape Lifesciences released its earnings results on May 21, 2025. The company reported $18.98 earnings per share for the quarter, beating the consensus estimate of N/A by $18.98.
Is ReShape Lifesciences overvalued?
According to Wall Street analysts ReShape Lifesciences’s price is currently Overvalued.
Does ReShape Lifesciences pay dividends?
ReShape Lifesciences does not currently pay dividends.
What is ReShape Lifesciences’s EPS estimate?
ReShape Lifesciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ReShape Lifesciences have?
ReShape Lifesciences has 2,385,960 shares outstanding.
What happened to ReShape Lifesciences’s price movement after its last earnings report?
ReShape Lifesciences reported an EPS of $18.98 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -13.514%.
Which hedge fund is a major shareholder of ReShape Lifesciences?
Currently, no hedge funds are holding shares in RSLS
ReShape Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.98%
12-Months-Change
Fundamentals
Return on Equity
-120.16%
Trailing 12-Months
Asset Growth
-21.24%
Trailing 12-Months
Company Description
ReShape Lifesciences
ReShape Lifesciences (RSLS) is a medical device company focused on the development and commercialization of innovative technologies for weight loss and metabolic health. The company operates within the healthcare and medical device sectors, offering a portfolio of minimally invasive products designed to treat obesity and related comorbidities. Their core products include the Lap-Band Adjustable Gastric Banding System and various accompanying support programs aimed at improving patient outcomes.
RSLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.Read More>